Harvard spinout Emulate will use the cash to further develop its organ-on-a-chip technology, having now raised nearly $225m in total.

Emulate, a US-based biotechnology developer spun out of Harvard University, raised $82m in a series E round led Northpond Ventures on Tuesday. Perceptive Advisors also contributed funding, bringing the company’s total capital to almost $225m. Emulate is developing in vitro on-a-chip models of human organs that replicate their function, in order to aid research in…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.